Navigation Links
Tibet Pharmaceuticals, Inc. Announces Intent to Go Private
Date:2/27/2012

NEW YORK, Feb. 27, 2012 /PRNewswire-Asia/ -- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced that,

 "In recent days, we noticed that a website mentioned about auctioning our operating entity's assets. These were untrue and incorrect announcements. Our company is in normal business operation. We're conducting our investigation on this mistaken report, and will keep our investors informed on the investigation result," said Mr. Hong Yu, CEO and Chairman of Tibet Pharmaceuticals. "The Company will take all necessary legal measures to defend itself against any untrue reports and to protect the interests of shareholders."

The Company also announced its intent to accept a "going private" proposal by Mr. Hong Yu, and cease its public company status. "In view of market bias towards Chinese companies listed in U.S. stock exchange and our past stock performance, I hereby make an offer to purchase TBET stocks not owned by me for $3.00 per share in cash,"said Mr. Hong Yu, "delisting details will be announced shortly".

Tibet Pharmaceuticals expects to continue to grow in China's fragmented pharmaceutical and traditional Tibetan medicine industries. The company is committed to establishing itself as a leading manufacturer and distributor of Tibetan medicine in China and believes that additional distribution channels will help enhance its completive advantages in the industry.

About Tibet Pharmaceuticals, Inc.

Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ: TBET - News) is an emerging specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals' products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company's 52,000 sq. ft. GMP-certified manufacturing facilities are located. The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals.

For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: White Paper, Investor Portal and Overview Video.

For more information on Tibet Pharmaceuticals, please visit:
http://www.tibetpharmaceuticals.com/

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts.

These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, changes in company valuations and investor perceptions of companies, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact:

Financial Communications
Trilogy Capital Partners - Asia
Darren Minton
President
Toll-free: 800-592-6067
info@trilogy-capital.com


'/>"/>
SOURCE Tibet Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX® in Canada, Australia, Brazil and Mexico
2. Acella Pharmaceuticals, LLC, Files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration
3. Omthera Pharmaceuticals, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference
4. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
5. Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
6. Acella Pharmaceuticals, LLC Announces Its Acquisition of the PRENATE® Family of Trademarks and Associated Intellectual Property
7. Omthera Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Kinex Pharmaceuticals Acquires Rights for Technology and Products from Hanmi Pharmaceuticals, in United States and European Union Territories
9. Block & Leviton LLP Investigates ISTA Pharmaceuticals, Inc.s Board of Directors for Possible Breaches of Fiduciary Duty
10. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
11. AMG 277 Discriminates Against S1P3 Receptor by 50-fold. S1P1 Lead Compounds Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Assets Generated by Epix Pharmaceuticals, Inc. and Amgen.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... 2016 ReportsnReports.com adds Global ... Devices of its online business intelligence library. This ... current state of the Titrator industry. The report ... definitions, classifications, Specifications, applications and industry chain structure. ... Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost Structure, ...
(Date:5/20/2016)... 20, 2016 - Revenue ... Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative ... This New Study Reveals Selling Opportunities and Revenue ... ,What is the future of biologics, especially ... and commercial analysis. Staying ahead in data and ...
(Date:5/20/2016)... , May 20, 2016 ... Review, H1 2016" market research report with comprehensive ... (Psoriasis Vulgaris), complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ...
Breaking Medicine Technology:
(Date:5/24/2016)... , ... (PRWEB) May ... three new members of its Advisory Board. Joining the Grow ... Kusch. “All three of them embody the mission of our organization ... very fortunate to have them as we continue to expand our ...
(Date:5/24/2016)... ... May 24, 2016 , ... Physical therapy is ... repairing the musculoskeletal and neuromuscular systems of the human body without recourse to ... providing treatments for physical therapy in New York, including dynamic neuromuscular stabilization ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades of experience, ... job, ensuring the best suited solution to meet regulatory requirements. Their professional staff ... lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and ...
(Date:5/24/2016)... ... May 24, 2016 , ... Eggsurance, the first ... relaunch of its community and education hub for women considering fertility preservation, as ... create a safe and welcoming place for women to find cycle buddies, get ...
(Date:5/24/2016)... ... May 24, 2016 , ... The Radiosurgery Society (RSS), a ... is recognizing five medical residents and students for their outstanding contributions to research ... awards will be presented at the 2016 SRS/SBRT Scientific Meeting taking place June ...
Breaking Medicine News(10 mins):